Attive care - Attive care
Rua Coronel Cacildo Arantes, 488, Chácara Cachoeira - Campo Grande -
MS | Zip Code: 79040452
Telephone: (67) 3314-2232 | CNPJ: 28.142.301/0001-79
Atendimento: Seg, Ter, Qua, Qui, Sex e Sáb - 08:00 às 18:00.
ARIOVALDO GOMES CPF: 004.831.431-54
Birth: Age: 40 Gender: Male Telephone: (67) 99981- E-mail:
11/27/1981 years 0666
Address: Rua Talles, 78, Jardim São Lourenço - Campo Grande Zip code: 79041-
- MS 560
POINT-OF-CARE-TESTING Service Date: 04/21/2022 - 08:02 AM
Test performed: CORONAVIRUS MOLECULAR ECO M SARS-COV-2
Result
CORONAVIRUS - RNA AMPLIFICATION (QUALITATIVE TEST)
NOT DETECTED
INDICATION FOR RUNNING THE TEST:
SAMPLE: Nasopharyngeal Mandatory testing for participation in sports events, events in general
Swab and travel
EQUIPMENT: Analisador ECO METHOD: RT-PCR LOT: Mnco0322020 REGISTER MS:
M10 EXPIRATION DATE: 07/2022 80954880172
HOW TO INTERPRET: ABOUT THE CONDITION: SYMPTOMS:
Detected (Positive) result suggests active infection COVID-19 (Coronavirus Disease) is an infectious Many people have only mild symptoms such as a
by the COVID-19 virus. It may occur even in the disease caused by the new Coronavirus (SARS- sore throat, cough and fever. The disease can be
absence of symptoms. Not Detected (Negative) COV-2). The main form of transmission of the new more serious for some people, causing pneumonia,
result suggests absence of infection by the COVID- coronavirus is by contact with an infected person, shortness of breath or difficulty breathing. In rarer
19 virus. It occures even in the presence of who transmits the virus through coughing, cases it can be fatal.
symptoms. Take this test result to your doctor for sneezing, saliva droplets or coryza. It is possible to Elderly people, people with cardiovascular disease or
evaluation. Inconclusive (Presumptive Positive) protect yourself by washing your hands frequently, diabetes, immunosuppressed and pregnant women
result suggests that SARS-CoV-2 nucleic acids may wearing a mask and social distancing. are more vulnerable to serious conditions.
be present and the sample should be retested. For
samples with an inconclusive result, additional
confirmatory testing may be required if it is
necessary to differentiate between SARS-CoV-2 and
SARS-CoV-1. Take this result to your doctor for
evaluation. The expected reference result for this
test is "Not Detected (Negative)".
Patient guidelines:
- The molecular COVID-19 test has specific indications only in some cases. See your test statement at the top of this report.
- ECO M SARS-CoV-2 contains primers and probes and internal control (IC) used in RT-PCR for the qualitative in vitro detection of SARS-CoV-2 RNA in
nasopharyngeal swab and oropharyngeal swab samples. A not detected (negative) result does not exclude the possibility of virus infection and a detected (positive)
result should not be used as the sole diagnostic resource, but should be interpreted in conjunction with the patient's clinical signs and symptoms. Detected and Not
Detected results can occur both in presence and absence of symptoms. The diagnosis must be made by the physician.
- The molecular COVID-19 test has limitations inherent to its methodology and, like any test, it may present false-negative or false-positive results. These results can
occur even when all the correct procedures are performed, so there is no guarantee that the test will run without failure. It may be necessary to retest in the laboratory,
as requested by the physician, for definition of diagnosis or treatment. This is a decision of the physician responsible for the patient care and does not mean that the
rapid test result is incorrect.
- This test detects the presence of genes in the target region ORF1ab and the E gene of the SARS-CoV-2 virus in human body, indicating infection by the new
coronavirus. Running the test does not eliminate the need for all preventive care and social isolation inherent in to each case. COVID-19 rapid test performed in
accordance with Anvisa RDC 377/2020 and RDC 302/2005. This procedure is not a diagnostic and does not replace medical consultation or laboratory tests.
- Clinical Test Performance: Results compared with results from a commercial molecular test. Sensitivity: 95.04% (121/115, 95%CI, 89.60%~97.71%). Specificity:
>99.99% (431/431, 95%CI, 99.12%~100%). Accuracy: 98.91% (552/546.95%CI,97.65%~99.5%). Some potential interferers such as antiviral drugs for
Influenza, Malaria, HCV, nasal sprays, anti-inflammatory drugs such as acetaminophen and ibuprofen and some antibiotics such as mupirocin and erythromycin
among others were tested and did not interfere in the test. Some potential interferents for cross-reaction were also tested, such as SARS-coronavirus, Influenza A,
Influenza B, Adenovirus, MERS coronavirus, Parainfluenza Virus, among others. With the exception of the SARS coronavirus, which showed 1x106 PFU/mL
interference, the other potential interferents did not cross-react.
ARIOVALDO GOMES Héron Emmanuel Passos Petris Kedma Cristina Rorigues Assunção
I declare that I received the guidelines regarding Technical Manager - CRF/PR - 18206 Regional Council: COREN - 001485935 /
this service. Clinicarx Laboratories Services MS Attive care
REPORT Nº: TLR-0007-0050-059902
Point-of-care-testing performed by: Kedma Cristina Rorigues Assunção Responsible Regional Council: COREN - 001485935 / MS Attive care - Attive
care
Clinicarx Laboratory Services | CNPJ: 26740121/0001-63
Avenida Marechal Humberto Alencar Castelo Branco, 131 - Curitiba - PR - CEP 82520-205
Registration CRF/PR: 26520 | Health Surveillance 04.234/2019 | CNES: 0029637
In case of doubts, write to: suporte@[Link] or get in touch with the healthcare professional who attended you.
Download our app and have your health care results accessible anytime, anywhere. Learn more at:
Promover serviços de saúde de qualidade a todos. Pag 1
[Link]
